Immunological changes induced by Toxoplasma gondii Glutathione-S-Transferase (TgGST) delivered as a DNA vaccine

Research in Veterinary Science

Volumn 99, Issue , 2015, Pages 157-164

  Wang, Shuai ^a   Hassan, Ibrahim A ^a   Liu, XinChao ^a   Xu, LiXin ^a   Yan, RuoFeng ^a   Song, XiaoKai ^a   Li, XiangRui ^a  

^a NANJING AGRICULTURAL UNIVERSITY   (China)

Author keywords

DNA vaccines; Glutathione S transferase; TgGST; Toxoplasma gondii

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 17; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PTGGST VACCINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; PROTOZOAL PROTEIN; PROTOZOAL VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TOXOPLASMA GONDII; TOXOPLASMOSIS; VACCINATION; ANIMAL; FEMALE; IMMUNOLOGY; PARASITOLOGY; TOXOPLASMA;

EUKARYOTA; MUS; TOXOPLASMA GONDII;

ANIMALS; FEMALE; GLUTATHIONE TRANSFERASE; MICE; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, DNA;

EID: 84925241886     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2014.12.006     Document Type: Article

References (59)

1. Alexander J., Scharton-Kersten T., Yap G., Roberts C., Liew F., Sher A. Mechanisms of innate resistance to Toxoplasma gondii infection. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1997, 352:1355-1359.
2. Alexander J., Jebbari H., Bluethmann H., Brombacher F., Roberts C. The role of IL-4 in adult acquired and congenital toxoplasmosis. International Journal for Parasitology 1998, 28:113-120.
3. Araujo F. Depletion of CD4+ T cells but not inhibition of the protective activity of IFN-gamma prevents cure of toxoplasmosis mediated by drug therapy in mice. The Journal of Immunology 1992, 149:3003-3007.
4. Araujo F., Huskinson J., Remington J. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 1991, 35:293-299.
5. Araujo F., Shepard R., Remington J. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. European Journal of Clinical Microbiology and Infectious Diseases 1991, 10:519-524.
6. Araujo F., Lin T., Remington J. Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice. European Journal of Clinical Microbiology and Infectious Diseases 1992, 11:71-73.
7. Araujo F., Slifer T., Remington J. Rifabutin is active in murine models of toxoplasmosis. Antimicrobial Agents and Chemotherapy 1994, 38:570-575.
8. Araujo F.G., Khan A.A., Remington J.S. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 1996, 40:1335-1337.
9. Bermudez L., Covaro G., Remington J. Infection of murine macrophages with Toxoplasma gondii is associated with release of transforming growth factor beta and downregulation of expression of tumor necrosis factor receptors. Infection and Immunity 1993, 61:4126-4130.
10. Bhopale G.M. Development of a vaccine for toxoplasmosis: current status. Microbes and Infection 2003, 5:457-462.
11. Calderaro A., Piccolo G., Gorrini C., Peruzzi S., Zerbini L., Bommezzadri S., et al. Comparison between two real-time PCR assays and a nested-PCR for the detection of Toxoplasma gondii. Acta Biomedica-Ateneo Parmense 2006, 77:75.
12. Callahan H., Crouch R., James E. Helminth anti-oxidant enzymes: a protective mechanism against host oxidants?. Parasitology Today 1988, 4:218-225.
13. Capron A., Capron M., Dombrowicz D., Riveau G. Vaccine strategies against schistosomiasis: from concepts to clinical trials. International Archives of Allergy and Immunology 2012, 124:9-15.
14. Champsi J., Young L., Bermudez L. Production of TNF-alpha, IL-6 and TGF-beta, and expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection. Immunology 1995, 84:549.
15. Chardes T., Bourguin I., Mevelec M., Dubremetz J., Bout D. Antibody responses to Toxoplasma gondii in sera, intestinal secretions, and milk from orally infected mice and characterization of target antigens. Infection and Immunity 1990, 58:1240-1246.
16. Chen J., Li Z.Y., Huang S.Y., Petersen E., Song H.Q., Zhou D.H., et al. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice. BMC Infectious Diseases 2014, 14:487.
17. Chen Z., O'Shea J.J. Th17 cells: a new fate for differentiating helper T cells. Immunologic Research 2008, 41:87-102.
18. Couper K.N., Roberts C.W., Brombacher F., Alexander J., Johnson L.L. Toxoplasma gondii-specific immunoglobulin M limits parasite dissemination by preventing host cell invasion. Infection and Immunity 2005, 73:8060-8068.
19. Dupont C.D., Christian D.A., Hunter C.A. Immune response and immunopathology during toxoplasmosis. Seminars in Immunopathology 2012, 34:793-813.
20. Gazzinelli R., Hakim F., Hieny S., Shearer G., Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. The Journal of Immunology 1991, 146:286-292.
21. Godard I., Darcy F., Deslee D., Dessaint J., Capron A. Isotypic profiles of antibody responses to Toxoplasma gondii infection in rats and mice: kinetic study and characterization of target antigens of immunoglobulin A antibodies. Infection and Immunity 1990, 58:2446-2451.
22. Gupta S., Bhandari Y.P., Reddy M.V., Harinath B.C., Rathaur S. Setaria cervi: immunoprophylactic potential of glutathione-S-transferase against filarial parasite Brugia malayi. Experimental Parasitology 2005, 109:252-255.
23. Hakim F.T., Gazzinelli R.T., Denkers E., Hieny S., Shearer G., Sher A. CD8+ T cells from mice vaccinated against Toxoplasma gondii are cytotoxic for parasite-infected or antigen-pulsed host cells. The Journal of Immunology 1991, 147:2310-2316.
24. Hassan I.A., Wang S., Xu L., Yan R., Song X., Li X. Immunoglobulin and cytokine changes induced following immunization with a DNA vaccine encoding Toxoplasma gondii selenium-dependent glutathione reductase protein. Experimental Parasitology 2014, 146C:1-10.
25. Hassan I.A., Wang S., Xu L., Yan R., Song X., XiangRui L. Immunological response and protection of mice immunized with plasmid encoding T. gondii glycolytic enzyme malate dehydrogenase. Parasite Immunology 2014, 36:674-683.
26. Hayashi H., Inoue Y., Tsutsui H., Okamura H., Nakanishi K., Onozaki K. TGF down-regulates IFN-production in IL-18 treated NK cell line LNK5E6. Biochemical and Biophysical Research Communications 2003, 300:980-985.
27. Hunter C.A., Bermudez L., Beernink H., Waegell W., Remington J.S. Transforming growth factor inhibits interleukin 12 induced production of interferon by natural killer cells: a role for transforming growth factor in the regulation of T cell independent resistance to Toxoplasma gondii. European Journal of Immunology 1995, 25:994-1000.
28. Israelski D.M., Remington J.S. Toxoplasmic encephalitis in patients with AIDS. Infectious Disease Clinics of North America 1988, 2:429-445.
29. Janssen R., van Wengen A., Verhard E., de Boer T., Zomerdijk T., Ottenhoff T.H., et al. Divergent role for TNF-α in IFN-γ-induced killing of Toxoplasma gondii and Salmonella typhimurium contributes to selective susceptibility of patients with partial IFN-γ receptor 1 deficiency. The Journal of Immunology 2002, 169:3900-3907.
30. Johnson L.L., Sayles P.C. Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infection and Immunity 2002, 70:185-191.
31. Kang H., Remington J.S., Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase. The Journal of Immunology 2000, 164:2629-2634.
32. Kelly M.N., Kolls J.K., Happel K., Schwartzman J.D., Schwarzenberger P., Combe C., et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infection and Immunity 2005, 73:617-621.
33. Khan A.Q., Chen Q., Wu Z.-Q., Paton J.C., Snapper C.M. Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2. Infection and Immunity 2005, 73:298-307.
34. Khan I., Ely K., Kasper L. Antigen-specific CD8+ T cell clone protects against acute Toxoplasma gondii infection in mice. The Journal of Immunology 1994, 152:1856-1860.
35. Khan I.A., Ely K.H., Kasper L.H. A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. The Journal of Immunology 1991, 147:3501-3506.
36. Lin J., Seguin R., Keller K., Chadee K. Transforming growth factor-beta 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology 1995, 85:400.
37. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS. Clinical Infectious Diseases 1992, 15:211-222.
38. Macpherson A., McCoy K., Johansen F., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunology 2008, 1:11-22.
39. Miyamoto M., Prause O., Sjöstrand M., Laan M., Lötvall J., Lindén A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. The Journal of Immunology 2003, 170:4665-4672.
40. Munoz M., Liesenfeld O., Heimesaat M.M. Immunology of Toxoplasma gondii. Immunological Reviews 2011, 240:269-285.
41. Parker S., Roberts C., Alexander J. CD8+ T cells are the major lymphocyte subpopulatlon involved in the protective immune response to Toxoplasma gondii in mice. Clinical & Experimental Immunology 1991, 84:207-212.
42. Passos S.T., Silver J.S., O'Hara A.C., Sehy D., Stumhofer J.S., Hunter C.A. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. The Journal of Immunology 2010, 184:1776-1783.
43. Pinon J., Toubas D., Marx C., Mougeot G., Bonnin A., Bonhomme A., et al. Detection of specific immunoglobulin E in patients with toxoplasmosis. Journal of Clinical Microbiology 1990, 28:1739-1743.
44. Rathaur S., Yadav M., Gupta S., Anandharaman V., Reddy M.V. Filarial glutathione-S-transferase: a potential vaccine candidate against lymphatic filariasis. Vaccine 2008, 26:4094-4100.
45. Robert-Gangneux F., Dardé M.-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clinical Microbiology Reviews 2012, 25:264-296.
46. Roberts C., Ferguson D., Jebbari H., Satoskar A., Bluethmann H., Alexander J. Different roles for interleukin-4 during the course of Toxoplasma gondii infection. Infection and Immunity 1996, 64:897-904.
47. Rodriguez J.B., Szajnman S.H. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opinion on Therapeutic Patents 2012, 22:311-333.
48. Sasai K., Aita M., Lillehoj H., Miyamoto T., Fukata T., Baba E. Dynamics of lymphocyte subpopulation changes in the cecal tonsils of chickens infected with Salmonella enteritidis. Veterinary Microbiology 2000, 74:345-351.
49. Schindler H., Diefenbach A., Röllinghoff M., Bogdan C. IFN-γ inhibits the production of latent transforming growth factor-β1 by mouse inflammatory macrophages. European Journal of Immunology 1998, 28:1181-1188.
50. Schöler N., Krause K., Kayser O., Müller R.H., Borner K., Hahn H., et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrobial Agents and Chemotherapy 2001, 45:1771-1779.
51. Sibley L., Adams L., Krahenbuhl J. Macrophage interactions in toxoplasmosis. Research in Immunology 1993, 144:38-40.
52. Sibley L.D., Ajioka J.W. Population structure of Toxoplasma gondii: clonal expansion driven by infrequent recombination and selective sweeps. Annual Review of Microbiology 2008, 62:329-351.
53. Silva N.M., Vieira J.C., Carneiro C.M., Tafuri W.L. Toxoplasma gondii: the role of IFN-gamma, TNFRp55 and iNOS in inflammatory changes during infection. Experimental Parasitology 2009, 123:65-72.
54. Song H., Yan R., Xu L., Song X., Shah M.A., Zhu H., et al. Efficacy of DNA vaccines carrying Eimeria acervulina lactate dehydrogenase antigen gene against coccidiosis. Experimental Parasitology 2010, 126:224-231.
55. Subauste C., Koniaris A., Remington J. Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii-infected cells. The Journal of Immunology 1991, 147:3955-3959.
56. Veerapathran A., Dakshinamoorthy G., Gnanasekar M., Reddy M.V.R., Kalyanasundaram R. Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Neglected Tropical Diseases 2009, 3:e457.
57. Xu Y., Zhang N.Z., Tan Q.D., Chen J., Lu J., Xu Q.M., et al. Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model. BMC Infectious Diseases 2014, 14:525.
58. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. The Journal of Experimental Medicine 2001, 194:519-528.
59. Zhao G., Zhou A., Lv G., Meng M., Sun M., Bai Y., et al. Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis. BMC Infectious Diseases 2013, 13:207.